Type of security: Stock
Sector: Health Care
Industry: Biotechnology: Biological Products (No Diagnostic Substances)
The data is delayed by 15 minutes.
Description: Coherus Biosciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. Its clinical stage pipeline consists of CHS-0214, an etanercept biosimilar candidate, which is in two Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis; CHS-1420, an adalimumab biosimilar candidate that has completed a Phase I study to treat psoriasis or rheumatoid arthritis; and CHS-1701, a pegfilgrastim biosimilar candidate, which has completed a Phase I study for the treatment of breast cancer patients exhibiting chemotherapy-induced neutropenia. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus Biosciences, Inc. in April 2012. Coherus Biosciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.
|Shares Outstanding||EPS||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||-63.81%||Sales Growth - Q/Q||-10.52%||P/E|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-50.75%||ROE||-203.75%||ROI|
|Current Ratio||2.77||Quick Ratio||Long Term Debt/Equity||Debt Ratio||1.36|
|Gross Margin||Operating Margin||-245.92%||Net Profit Margin||-274.14%||Dividend Payout Ratio|
|Cash From Financing Activities||-730 K||Cash From Investing Activities||-1.31 M||Cash From Operating Activities||-33.06 M||Gross Profit|
|Net Profit||-40.73 M||Operating Profit||-36.75 M||Total Assets||153.15 M||Total Current Assets||143.9 M|
|Total Current Liabilities||51.91 M||Total Debt||Total Liabilities||115 M||Total Revenue||5.81 M|
|High 52 week||23.37||Low 52 week||8.38||Last close||19.15||Last change||-2.84%|
|RSI||61.92||Average true range||1.22||Beta||1.59||Volume||340.72 K|
|Simple moving average 20 days||6%||Simple moving average 50 days||-0.5%||Simple moving average 200 days||29.13%|
|Performance Week||-4.35%||Performance Month||-3.04%||Performance Quart||9.62%||Performance Half||36.01%|
|Performance Year||4.36%||Performance Year-to-date||111.6%||Volatility daily||4.49%||Volatility weekly||10.05%|
|Volatility monthly||20.59%||Volatility yearly||71.32%||Relative Volume||232.26%||Average Volume||1.11 M|
|New High||New Low|
2019-11-12 08:18:01 | The Zacks Analyst Blog Highlights: Coherus, Incyte, ACADIA and Celgene
2019-11-11 09:28:02 | 4 Biotech Stocks That Could Keep Beating Wall Street
2019-11-08 09:30:00 | Coherus BioSciences Announces New Employment Inducement Grants
2019-11-07 04:57:35 | Edited Transcript of CHRS earnings conference call or presentation 6-Nov-19 9:30pm GMT
2019-11-06 18:15:11 | Coherus BioSciences CHRS Q3 Earnings and Revenues Surpass Estimates
2019-11-06 16:01:00 | Coherus Acquires Commercial Rights for Leading Lucentis Biosimilar in the United States
2019-10-29 15:16:07 | Investors Can Find Strong Stocks with our First Profit Screen
2019-10-28 11:18:33 | 3 ‘Perfect 10’ Biotech Stocks to Buy Amid Volatile Market Environment
2019-10-26 13:22:47 | Hedge Funds Have Never Been More Bullish On Coherus Biosciences Inc CHRS
2019-10-21 07:44:17 | Are Insiders Selling Coherus BioSciences, Inc. NASDAQ:CHRS Stock?
2019-10-18 09:30:05 | Coherus BioSciences Announces New Employment Inducement Grants
2019-10-15 09:30:00 | Coherus BioSciences to Report Third Quarter Financial Results on November 6th
2019-09-25 16:37:17 | How This IBD Stock Of The Day Is Rattling Medical Giants Amgen, Mylan
2019-09-20 09:30:00 | Coherus BioSciences Announces New Employment Inducement Grants
2019-09-10 15:18:07 | Investors Can Find Big Returns with this First Profit Screen
2019-09-10 09:00:01 | Coherus BioSciences CHRS Upgraded to Buy: Here's What You Should Know
2019-08-28 16:05:17 | Stocks To Watch: Is Biosimilars Leader Coherus Biosciences Set To Rebound?
2019-08-28 13:31:00 | Breakout Stocks & Technical Analysis
2019-08-22 09:30:00 | Coherus BioSciences Announces New Employment Inducement Grants
2019-08-22 09:11:27 | Is Coherus BioSciences NASDAQ:CHRS Using Too Much Debt?
2019-08-02 11:22:12 | Edited Transcript of CHRS earnings conference call or presentation 1-Aug-19 8:30pm GMT
2019-08-01 19:52:12 | Coherus BioSciences, Inc. CHRS Q2 2019 Earnings Call Transcript
2019-08-01 18:55:10 | Coherus BioSciences CHRS Beats Q2 Earnings and Revenue Estimates
2019-07-31 13:48:03 | Steven Cohen Charges Into Chiasma
2019-07-29 20:30:00 | Coherus BioSciences Reports Victory in Pegfilgrastim Patent Dispute
2019-07-19 09:30:00 | Coherus BioSciences Announces New Employment Inducement Grants
2019-07-12 12:13:04 | Top Ranked Momentum Stocks to Buy for July 12th
2019-07-08 16:51:00 | Why Deutsche Bank, Intra-Cellular Therapies, and Coherus BioSciences Slumped Today
2019-07-08 13:30:00 | Here's Why Coherus BioSciences Is Falling Today
2019-07-08 10:44:04 | Are Investors Undervaluing Coherus BioSciences, Inc. NASDAQ:CHRS By 20%?
2019-07-08 09:00:00 | Coherus BioSciences to Report Second Quarter Financial Results on August 1st
2019-06-27 09:00:01 | Coherus BioSciences CHRS Upgraded to Strong Buy: Here's Why
2019-06-21 09:30:00 | Coherus BioSciences Announces New Employment Inducement Grants
2019-06-14 17:59:55 | Hedge Funds Have Never Been This Bullish On Coherus Biosciences Inc CHRS
2019-06-11 08:06:09 | See what the IHS Markit Score report has to say about Coherus BioSciences Inc.
2019-06-10 08:07:02 | See what the IHS Markit Score report has to say about Coherus BioSciences Inc.
2019-06-06 08:05:34 | See what the IHS Markit Score report has to say about Coherus BioSciences Inc.
2019-06-04 08:03:49 | See what the IHS Markit Score report has to say about Coherus BioSciences Inc.
2019-05-23 10:38:02 | Amgen AMGN Offers to Acquire Drug Discovery Platform
2019-05-23 09:30:00 | Coherus BioSciences Announces New Employment Inducement Grants
2019-05-22 09:55:30 | Did Coherus BioSciences's NASDAQ:CHRS Share Price Deserve to Gain 29%?
2019-05-22 09:30:00 | Coherus BioSciences Management to Present at Jefferies 2019 Global Healthcare Conference
2019-05-21 09:04:52 | See what the IHS Markit Score report has to say about Coherus BioSciences Inc.
2019-05-13 11:30:00 | 2 Drug Stocks to Buy as Health Care Suffers, According to JPMorgan